Since the first discovery of cancer-associated IDH1 and IDH2 mutations, IDH-inhibitor drugs are available for patients with AML harboring these mutations, both in newly diagnosed patients not eligible for intensive therapy in which Ivosidenib (IDH1 inhibitor) accounts for a rate of 42% of complete remission/partial hematologic recovery and overall survival of 12% and in those in the relapsed/refractory setting in which Ivosidenib and Enasidenib account for a rate of 30% of complete remission/partial hematologic recovery and a median overall survival of 9 months [10,55,63]. The gene discussed is IDH2; the disease is cancer.